Strategies to inhibit iNOS activity, such as small-molecule inhibitors or RNA-based therapies, are being explored to suppress angiogenesis, reduce tumor growth, and restore immune surveillance within the tumor microenvironment [67,68]. This evidence concerns the gene NOS2 and neoplasm.